$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026The Central Bank of Iceland , Financial Supervision has approved Oculis’s prospectus related to the admission of its ordinary shares to trade on the Nasdaq Iceland Main Market; Oculis will announce the first day of trading with at least one day advance notice- On-track to report topline data from OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED) in Q2 2024
"We are pleased to become one of the few dual-listed biotech companies in the
In connection with the Financing, Oculis accepted Subscription Offers from a syndicate of new Icelandic institutional and existing investors. Closing and settlement of the Financing is expected on
Oculis submitted an application to Nasdaq Iceland to admit its ordinary shares for trading on the Nasdaq Iceland Main Market (“Main Market”) under the ticker symbol “OCS.” On
Oculis’s ordinary shares are currently listed on the Nasdaq Global Market in the
Arctica Finance ehf. provided process oversight for the listing of Oculis’s shares on the Main Market and served as Oculis’s financial advisor with regard to the Financing. BBA//Fjeldco,
The Shares are being offered and sold by Oculis in a registered direct offering pursuant to a shelf registration statement on Form F-3 (File No. 333-278409), including a base prospectus, previously filed with the
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. There will be no public offering of Shares in
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’s highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in
For more information, please visit: www.oculis.com
Oculis Contacts
Ms.
sylvia.cheung@oculis.com
Investor & Media Relations
cdavis@lifesciadvisors.com
1-212-915-2577
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the commencement of trading of Oculis’s ordinary shares on the Main Market and the use of proceeds, timing and closing of the Financing, and the potential of Oculis to deliver anticipated clinical readouts, including the expected OCS-02 RELIEF Phase 2b topline data readout. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that are described in the Risk Factors sections of the prospectus supplement for the Financing to be filed with the
Source:
2024 GlobeNewswire, Inc., source